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Abstract 
Introduction: In Romania, there is no acromegaly national register and there are no nationwide 
data available. However, some studies have reported the control rates in the country’s main 
referral centres. Our aim was to assess the overall control rate in our tertiary referral centre. Also, 
we assessed the control rate in the last three years, and we compared the results with our 
previous reports. 
Material and methods: We reviewed the charts of 186 patients with acromegaly assessed in our 
department between January 1st, 2012 and May 31st, 2019.  We also compared the control rates 
for patients treated between April 1st, 2016 and May 31st, 2019 with historical controls (assessed 
between January 1st, 2012 and March 31st, 2016).  
Results: Primary analysis: There were 19 untreated and 167 treated patients, mean age 52.46 
years, surgery being the most commonly used treatment. The surgical cure rate was 14.8%, and 
disease control with medical treatment was 35.3%. Secondary analysis: In the first group there 
were 45 patients, surgery also being the most commonly used treatment. The surgical cure rate 
was 26.9%, and disease control was 30.4%. In the second group (historical controls) there were 
42 patients, surgery being the most commonly used treatment. The surgical cure rate was 9.7%, 
and disease control with medical treatment was 15.4%. Random GH and IGF-1 after surgery 
were lower in the first group (p < 0.05) 
Conclusions: Changes in the Romanian protocol and highly specialised pituitary centres has 
improved the cure rate and disease control in patients with acromegaly.  
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Introduction 
Acromegaly disease control has shown a significant improvement in the last years, 
particularly with multimodal therapy, including surgery, medical therapies, and radiotherapy [1]. 
Despite that, there is still a high variability of control rates in different centres [2–5] and 
countries [6–9]. Also, significant differences have been reported between sponsored clinical 
trials and real-life studies [6, 7, 10–12]. These large differences may be caused by different 
treatment protocols available in each country, which allow full reimbursement of treatment only 
in selected patients [6, 7, 12, 13]. 
In Romania, there is no acromegaly national register and there are no nationwide data 
available. However, some studies reported the control rates in the main referral centres of the 
country [14–16]. 
A study previously carried out in our centre showed disappointing results, with an overall 
control rate of 28% [16], significantly lower than in other European national registers [6, 9–12, 
17]. These results are mostly due to poor surgical outcome (surgical cure rate 9.7%) [16], also 
lower than in the available national registries [6, 9, 12]. 
After the publication of previous studies, the Romanian treatment protocol for acromegaly 
was changed, so that the combination of somatostatin analogues (SSA) and growth hormone 
antagonist (Pegvisomant), and second-generation SSA (Pasireotide) became available and fully 
reimbursed by health insurance. Also, some new centres specialising in pituitary surgery became 
available. 
Our aim was to assess the overall control rate in our tertiary referral centre. Also, we 
assessed the control rate in the last three years, with new available therapeutic options, and 
compared the results with our previous reports. 
  
Material and methods 
Subjects 
We reviewed the charts of all patients with confirmed acromegaly that were assessed at 
least once in our department between January 1st, 2012 and May 31st, 2019. During this period, 
we assessed 186 patients with confirmed acromegaly. After exclusion of 19 patients who were 
not assessed after at least one treatment, we observed the surgical cure rate and overall disease 
control in the remaining 167 treated patients (primary analysis) (Tab. 1). 
In the secondary analysis we evaluated only the patients diagnosed after January 1st,  2012 
and compared the control rates for patients diagnosed and treated after the new reimbursement 
protocol (Group 1 — between April 1st, 2016 and May 31st, 2019) with historical controls 
(Group 2 — patients diagnosed, treated, and assessed between January 1st, 2012 and March 31st, 
2016). Group 1 consisted of 45 patients with confirmed acromegaly, for 35 of whom we had 
post-treatment data. Group 2 consisted of 57 patients with confirmed acromegaly, for 42 of 
whom we had post-treatment data (Tab. 1). 
Acromegaly diagnosis and control 
Acromegaly diagnosis was made according to Endocrine Society guidelines (18) by 
elevated age-adjusted insulin-like growth factor-1 (IGF-1) and confirmed by lack of suppression 
of growth hormone (GH) below 1 ng/mL following documented hyperglycaemia during an oral 
glucose load test. Remission of acromegaly after surgery was defined also according to 
Endocrine Society guidelines as random GH < 1 ng/mL and normal age adjusted IGF-1. If the 
post-surgical GH was higher than 1 ng/mL, oral glucose load test was performed, and remission 
was considered if GH was suppressed below 0.4 ng/mL [18]. Control of acromegaly was defined 
according to Endocrine Society guidelines: a random serum GH < 1 ng/mL and an age-
normalised serum IGF-1 value. The GH and IGF-1 values used for calculation of the control rate 
were those at the last evaluation [18]. 
 
GH and IGF-1 assays 
Starting in January 2012 the C.I. Parhon National Institute of Endocrinology used the same 
assays for serum growth hormone (GH) and IGF-1 measurement according to the Endocrine 
Society Guidelines for Acromegaly. 
We measured serum GH using a chemiluminescence assay (Liaison, Sallugia, Italy). The 
assay is referenced to the WHO Second International Standard 98/574 for somatropin (22-kDa 
recombinant DNA-derived materials), with a functional sensitivity of 0.05 ng/mL and an 
analytical sensitivity of 0.009 ng/mL.  
We measured serum IGF-1 using a Liaison IGF-1 chemiluminescence assay (DiaSorin, 
Sallugia, Italy). The assay is referenced to the 02/254 International Standard for Insulin-like 
Growth Factor-I NIBSC, with functional sensitivity of 15 ng/mL and an analytical sensitivity of 
3 ng/mL. 
Statistics  
Data are presented as number (percentage) or as median (25th–75th percentile). We used the 
Mann-Whitney test to analyse differences between paired groups, and covariance analysis to 
assess differences between groups with covariates, for data with normal distribution.   
 
Results 
Primary analysis 
Between January 1st, 2012 and May 31st, 2019 we assessed 186 patients with newly or 
previous diagnosed acromegaly, 60 males and 126 females, with mean age of 55.48 (± 12.9) 
years. There were 19 untreated and 167 treated patients. Of the 167 treated patients 148 (88.6%) 
had surgery, 70 (41.9%) had radiotherapy, and 109 (65.2%) were receiving medical treatment at 
their last evaluation (37 Octreotide LAR, 19 Lanreotide LAR, 9 Pasireotide LAR, 7 
Pegvisomant, 17 Cabergoline, 20 combination of SSA and Pegvisomant) (Tab. 1). 
Of the 148 patients who underwent pituitary surgery, 38 (25.6%) had normal GH, 27 
(18.2%) patients had a normal age- and sex-adjusted IGF-1, and 22 (14.8%) had both normal 
IGF-1 and GH after surgery. 
Of the 109 patients receiving medical therapy 49 (48.0%) had a normal age-adjusted IGF-
1. Of the 82 patients receiving medical therapy not containing pegvisomant GH, control (by 
random GH < 1 ng/mL) was obtained in 50 (60.9%) patients. Both GH and IGF-1 control were 
obtained in 29 (35.3%) patients.  
Of the 70 patients treated with radiotherapy, 20 (28.5%) had normal GH and 12 (17.1%) 
had normal IGF-1. All of the patients with normal IGF-1 also had normal GH (17.1% cure rate). 
Overall, 108 (77%) patients monitored by random GH had normal GH at their last visit, 88 
(52%) had normal IGF-1, and 78 (46.7%) had both normal GH and IGF-1 at their last visit. 
 
Secondary analysis 
In group 1 (diagnosed between April 1st, 2016 and May 31st, 2019) there were 45 patients 
(13 males) with mean age of 51.32 years, of whom 36 were assessed after at least one treatment: 
26 (72.2%) patients treated by surgery, 22 (61.1%) patients with medical treatment (SSA, 
cabergoline, or combination of SSA with pegvisomant), and five (13.8%) patients treated with 
radiotherapy. Of the 26 patients treated by surgery, 12 (46.1%) patients had normalised GH, and 
seven (26.9%) had normal IGF-1 after surgery. All seven (26.9%) patients with normal IGF-1 
had also random GH. Of the 23 patients receiving medical treatment, 13 (56.5%) had normal GH 
and seven (30.4%) had normal age-adjusted IGF-1. Also, all seven (30.4%) patients had both 
normal age-adjusted IGF-1 and GH. After at least one treatment (surgical or medical), in the 
second group 25 (56.5%) had normal GH and 14 (38.8%) had normal age-adjusted IGF-1. The 
overall disease control rate in the first group was 38.8% (14 patients had both normal GH and 
IGF-1). 
In group 2 (diagnosed between January 1st, 2012 and March 31st, 2016) there were 42 
patients (11 males), with mean age 52.46 years, assessed after at least one treatment: 41 (97.6%) 
surgery, 26 (61.9%) medical therapy, and eight (19.0%) radiotherapy. Of the 41 surgically 
treated patients, 10 (24.3%) had normalised GH, six (14.6%) had normal age- and sex-adjusted 
IGF-1, and four (9.7%) had normalised GH and IGF-1. Of the 26 patients receiving medical 
treatment, 11 (42.3%) had normal GH, five (19.2%) had normal IGF-1, and four (15.4%) had 
normal GH and IGF-1. After at least one treatment, in the second group, 20 patients (47.6%) had 
normalised GH, 11 (26.2%) had normalised IGF-1, and in eight both GH and IGF-1 were normal 
(19.0%). 
Both pre-surgery and post-surgery IGF-1 and GH values were available in 21 patients in 
the first group and in 41 patients in the second group.  
Although median GH was similar between the two groups, median GH after surgery was 
lower in the first group (p < 0.05) (see Fig. 1). Also, IGF-1 after surgery was lower in the first 
group, using covariance analysis (p < 0.05) (see Fig. 1).  
Pre and post medical treatment GH and IGF-1 values were available in 15 patients in the 
first group and 26 patients in the second group. Regarding medical treatment efficacy, we 
compared basal GH before medical treatment and after medical treatment between the two 
groups and observed that in the first group the mean GH before treatment was 5.64 ng/mL and in 
the second group it was 7.21 ng/mL. After medical treatment the mean random GH was 2.51 
ng/mL in the first group and 3.99 ng/mL in the second group. Mean IGF-1 before medical 
treatment in the first group was 2.4  ULN and in the second group was 3.1  ULN. After 
receiving medical treatment the mean IGF-1 was 1.6  ULN in the first group and 1.8  ULN in 
the second group. Covariance analysis resulted in there being no difference between the two 
groups.  
 
Discussion 
Our study presents the overall control rate of acromegaly in a sample of 186 patients 
assessed in a single tertiary centre in Romania between January 1st, 2012 and May 31st, 2019. 
Also, we present the evolution of the control rate of GH and IGF1 in patients diagnosed in the 
last three years.     
Surgery was the preferred treatment of acromegaly. In our study 88.6% of patients 
underwent pituitary surgery, a proportion higher than in other countries (Mexico 70% [7], 
Bulgaria 85.8% [19], Spain 84% [6], France 80% [9], Sweden 64% [11]). This may be explained 
by the fact that in Romania, medical treatment is reimbursed only in patients who have 
undergone pituitary surgery. 
65.2% of patients were on medical treatment at their last evaluation, a lower percentage 
than in Spain (74%) [6] but higher than in some other countries (France 49.6% [9], Sweden 45% 
[11]). 
Radiotherapy (41.9% of patients) was used more extensively than in other countries 
(Germany 22% [12], France 17% [9], USA 20% [9]). This difference may also be explained by 
the absence of widely spread SSA treatment until 2009 in Romania. 
The surgical cure rate was 14.8% in our study, lower than in other studies made in different 
countries, which vary from 52 to 72% in centres presenting data on more than 100 patients [20]. 
Overall disease control (normal GH and IGF-1) was obtained with single or multimodal therapy 
in 46.7% of patients, also lower than in other countries (Finland 76% ], Belgium 56% [10], 
Canada 70% [8], UK 72% [17], Germany 72% [12]), but higher than in the previous study made 
in our centre (28.6%) (16). This progress in disease control may be explained by the change in 
the Romanian protocol of treatment, which now fully reimburses second-generation SSA and the 
combination of SSA and pegvisomant.   
In patients diagnosed in the last three years, who received at least one treatment, surgery 
was still the most used treatment — 26 (72.2%) patients; medical therapy was used in 22 
(61.1%) patients, and only five (13.8%) patients received radiotherapy. 
We observed that remission after surgery was higher in patients diagnosed after March 
2016. GH was normalised in 46.1% vs. 24.14%, IGF-1 in 26.9% vs. 14.6%, and both GH and 
IGF-1 in 26.9% vs. 9.7%. This may be caused by a higher referral of patients to highly 
specialised centres in pituitary surgery. Also, disease control with medical treatment was higher 
in patients assessed in our clinic after March 2016. IGF-1 was normalised in 30.4% vs. 19.2%, 
GH in 56.5% vs. 47.6%, and both GH and IGF-1 in 30.4% vs. 15.4%. The control rate in the first 
group of patients was also higher than in the second group (38.8% vs. 19.2%). We also found 
that surgical outcome in terms of lowering IGF-1 was better in the first group (p < 0.05), and also 
random GH after surgery was lower in the first group (p < 0.05).  
Although the control rate with medical treatment was also higher in the first group, there is 
no difference in IGF-1 lowering with medical treatment between the two groups, so we can 
assume that the better disease control with medical treatment is also caused by better surgical 
outcome. Also, the lack of difference in IGF-1 lowering with medical treatment can also be 
caused by the shorter time of follow-up in the first group and the lack of full dose escalation in 
SSA.  
 
Conclusion 
Although disease control of acromegaly has improved in recent years in our tertiary centre, 
it remains lower than in other countries. Despite that, changes in Romanian protocol treatment 
seem to improve overall disease control in the long run, and highly specialised pituitary surgery 
centres improve the short-term outcome, with a higher cure rate and improvement in lowering 
IGF-1 and random GH. Longer follow-up studies need to be performed in order to have a proper 
dose escalation of SSA, with the addition of GH receptor blocker to the treatment.  
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Table 1. Cure rate 
  
All patients January 1st, 2012–
March 31st, 2016 
April 1st, 2016–
May 31st, 2019 
Patients assessed, n 186 57 45 
Patients treated, n (%) 167 (89.7%) 42 (73%) 35 (77%) 
Surgery, n (% of treated) 148 (88.6%) 41 (97%) 26 (72.2%) 
Normal GH, n (% of surgery) 38 (25.6%) 10 (24.4%) 12 (46.1%) 
Normal IGF-1, n (% of surgery) 27(18.2%) 6 (14.6%) 7 (26.9%) 
Cured, n (% of surgery) 22 (14.8%) 4 (9.7%) 7 (26.9%) 
Medical treatment, n (% of 
treated) 
109 (65.2%) 26 (63.4%) 22 (61.1%) 
Controlled GH, n (% of medical 
treatment*) 
50 (60.9%) of 82 11 (42.3%) 13 (56.5%) 
Controlled IGF-1, n (% of 
medical treatment) 
49 (48.0%) 5 (19.2%) 7 (30.4%) 
Controlled IGF1 & GH, n (% of 
medical treatment*) 
29 (35.3%) 4 (15.4%) 7 (30.4%) 
Radiotherapy, n (% of treated) 70 (41.9%) 8 (19%) 5 13.8% 
Overall control rate    
GH* 108 (77.0%) 20 (47.6%) 24 (56.5%) 
IGF-1 88 (52%) 11 (26.2%) 14 (38.8%) 
GH & IGF-1* 78 (46.7%) 8 (19%) 14 (38.8%) 
 
Data are presented as n (%); *GH or GH&IGF-1 control rate refers only to patients not receiving 
growth hormone antagonist treatment. GH — growth hormone; IGF-1 — insulin-like growth 
factor 1 
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Figure 1. Preoperative (non-dashed) and postoperative (dashed) GH and IGF-1 in patients 
operated before 2016 (group 2 — white boxplots) or after 2016 (group 1 — grey boxplots). 
Dashed horizontal lines stand for normal values for both GH and IGF-1. Note that the GH axis is 
logarithmic. GH — growth hormone; IGF-1 — insulin-like growth factor 1 
 
